The H1 reports of Chinese listed companies in 2022 have all been revealed. Through the data collation, Andon Health, Assure Tech, Easy Diagnosis, Alltest Biotech, YHLO Biotech, Bioperfectus Technologies, Labway Clinical Laboratory, Hybribio Biotech and Wondfo Biotech, have increased their revenue by more than 100% in 2022 h1 compared to the same period of the previous year.

In terms of figures, Andon Health was ranked as the top ivd revenue in 2022 with revenue of CNY 23.367 billion, an increase of 3989.07% over the same period of the previous year. Assure Tech ranked second with CNY 5.93 billion, an increase of 1100.35% over the same period of the previous year, and Easy Diagnosis ranked third with CNY 5.253 billion, an increase of 360.27% over the same period of the previous year.